Furthermore, we developed aAVCs containing two or three cancer antigens (PSMA, PSA, and PAP) aiming to induce multiple types of CD8+ T cells, thereby preventing tumor cells from evading immune detection. The gene discussed is CD8A; the disease is neoplasm.